The Libin Cardiovascular Institute of Alberta‘s Dr. Anne Gillis, Professor of Medicine, a scholar of the Alberta Heritage Foundation for Medical Research and the Medical Director of Cardiac Pacing and Electrophysiology, wrote an editorial in the New England Journal of Medicine on the topic of Angiotensin-Receptor Blockers for Prevention of Atrial Fibrillation.
New England Journal of Medicine editorial by Dr. Gillis – LINK
New England Journal of Medicine – study by Marcello Diertori et al. – LINK
MedPage Today interviewed Dr. Gillis on this study, and on her comments in the editorial. Following is an excerpt:
But these results, from the first large, prospective randomized trial, “appear to provide strong evidence that valsartan (Diovan) and possibly other ARBs do not prevent the recurrence of atrial fibrillation in this patient population,” she said.
Since only 7.9% of study participants had heart failure or left ventricular systolic dysfunction — a population that might have benefited most, according to earlier studies — the results from this trial can’t be extrapolated to those patients, Dr. Gillis added.
To read the rest of the article, and also to hear a recording of an interview with Dr. Gillis, go to MedPage Today – LINK